This September, three key phase 3 readouts could shake up their respective markets. With data expected for ALGS, CHRS, and ABOS, investors should keep a close watch on these critical clinical trial results. As we head toward March and September 2027, the stakes are high for Chronic Hepatitis B Infection, Hepatocellular Carcinoma, and Alzheimer Disease.
Upcoming Phase 3 Readouts: Key Insights and Analysis
The full Phase 2 and Phase 3 readouts to watch
| Date | Ticker | Drug | Indication | Phase | PoA |
|---|---|---|---|---|---|
| 2027-03 | ALGS | ALG-000184, TDF (-24.1% run-up) | Chronic Hepatitis B Infection | PHASE2 | n/a |
| 2027-09 | CHRS | Casdozokitug, Toripalimab, Bevacizumab (+15.7% run-up) | Hepatocellular Carcinoma | PHASE2 | n/a |
| 2026-10 | ABOS | sabirnetug, Placebo (+8.6% run-up) | Alzheimer Disease | PHASE2 | n/a |
| 2026-10-31 | ANNX | Vonaprument, Sham Administration | Geographic Atrophy | PHASE3 | n/a 🔒 |
| 2027-04 | MNOV | MN-166, placebo | Amyotrophic Lateral Sclerosis | PHASE2 | n/a 🔒 |
| 2026-12-31 | MNOV | MN-001, MN-001 placebo | Diabetes Mellitus, Type 2 | PHASE2 | n/a 🔒 |
| 2027-08-31 | CMPX | CTX-009, Paclitaxel | Biliary Tract Cancer | PHASE2 | n/a 🔒 |
| 2026-11 | ATOS | (Z)-endoxifen, goserelin | Breast Neoplasms | PHASE2 | n/a 🔒 |
| 2028-01 | ACIU | Placebo, ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional) | Parkinson Disease | PHASE2 | n/a 🔒 |
| 2027-09 | AGEN | Botensilimab, Balstilimab, Standard of Care | Metastatic Colorectal Cancer | PHASE2 | n/a 🔒 |
| 2028-02 | AGEN | Botensilimab, Balstilimab | Advanced Melanoma | PHASE2 | n/a 🔒 |
ALGS: The March 2027 Phase 2 Results for ALG-000184
ALGS is preparing for a phase 2 readout of its drug ALG-000184 for Chronic Hepatitis B Infection in March 2027. Currently, the stock has dropped by 24.1%, indicating bearish sentiment as the trial approaches. Investors may be worried about the drug's efficacy or safety, crucial factors as we near the readout. This trial is vital for gauging the drug's potential as a treatment where existing options fall short. Investors will scrutinize efficacy and any distinguishing mechanism of action that sets ALG-000184 apart from current therapies. Depending on the outcomes, this trial could significantly alter ALGS's market valuation.
CHRS: Anticipating Phase 2 Readout for Casdozokitug
CHRS is set for a phase 2 readout in September 2027, focusing on a combination therapy with Casdozokitug, Toripalimab, and Bevacizumab for Hepatocellular Carcinoma. The stock has risen 15.7%, indicating growing investor confidence. This combination therapy targets multiple cancer pathways, potentially offering a more comprehensive treatment for patients. The market is eager to see the safety and efficacy profile, especially given the challenges of treating Hepatocellular Carcinoma. If the results show significant improvement over existing therapies, CHRS shares could be revalued substantially, making this a critical event to watch.
ABOS: Insights into the Phase 2 Readout for Sabirnetug
ABOS will present phase 2 clinical trial results for sabirnetug in Alzheimer Disease treatment in October 2026. The stock has seen an 8.6% rise, showing a cautious but positive market sentiment. Alzheimer Disease is a tough nut to crack, with a dire need for effective treatments. The trial results will be analyzed for their immediate impact on ABOS's stock and their broader implications on Alzheimer treatment. Investors will be keen on the drug's mechanism of action and its potential to alter disease progression. A positive outcome could put ABOS at the forefront in this competitive field, while setbacks might cause notable volatility.
Gated Items: A Look Ahead to Critical Trials
Beyond the immediate phase 2 readouts, several critical items are on the horizon. ANNX is gearing up for a phase 2 trial readout of Vonaprument for Geographic Atrophy on October 31, 2026. This is significant given the treatment challenges of the disease. Similarly, MNOV will report on MN-166 for Amyotrophic Lateral Sclerosis in April 2027. The urgency for ALS therapies means this could have substantial implications for both the company and patients. Trials from CMPX for Biliary Tract Cancer and ATOS for Breast Neoplasms are expected to offer insights into their indications by late 2026 and into 2027. Each trial could influence future treatment strategies and investor perspectives.
Market Implications: Navigating the Risks and Opportunities
Approaching these phase 2 readouts, market dynamics for ALGS, CHRS, and ABOS are growing more complex. Each company faces distinct challenges, from cash runway issues to potential stock price swings based on trial outcomes. Notably, five companies we're tracking have less than a year of cash left. A complete response letter could force a capital raise at unattractive valuations, heightening investor risk. The interplay between trial outcomes and broader market sentiment can add to volatility. Investors should stay alert, assessing both trial data and the financial health of these companies during this critical time.
Conclusion: Preparing for the Phase 3 Readout Landscape
The upcoming phase 3 readouts will shape the future for each of these companies. The clinical trial results for ALGS, CHRS, and ABOS will affect stock prices and could alter treatment landscapes in their respective fields. Investors should stay informed and ready for the possible implications of these readouts, as they could lead to new investment opportunities or signal caution.
The bottom line
The upcoming phase 3 readouts represent critical junctures for these companies and their investors.
Frequently asked questions
What is the significance of the upcoming phase 3 readouts?
The phase 3 readouts will provide critical data on drug efficacy and safety, influencing market valuations and treatment options.
How do run-up percentages affect investor sentiment?
Run-up percentages indicate market expectations; positive run-ups suggest confidence, while negative run-ups may reflect concerns.
What should investors consider regarding cash runway?
Investors should assess a company's cash runway to understand potential dilution risks and financial stability ahead of trial results.
Why are phase 2 results important?
Phase 2 results are crucial for determining a drug's potential effectiveness and safety before moving to larger phase 3 trials.